GlassScriptPhysician profile
Christopher G Holt
NPI 1992860977
$5,225.69
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,134 · 2020: $1,510 · 2021: $1,508 · 2022: $73.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,755.52 | 2019-2021 | |
| Gilead Sciences, INC. | $1,386.95 | 2019-2021 | |
| Janssen Biotech, INC. | $442.91 | 2019-2021 | |
| Theratechnologies INC. | $382.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $298.38 | 2019-2021 | |
| Janssen Products, LP | $199.90 | 2020-2021 | |
| Emd Serono, INC. | $196.88 | 2019-2021 | |
| Merz North America, INC. | $188.72 | 2019 | |
| Edwards Lifesciences Corporation | $93.69 | 2020-2022 | |
| Lilly USA, LLC | $67.52 | 2020-2021 | |
| Acerus Pharmaceuticals Corporation | $53.57 | 2021 | |
| Antares Pharma, INC. | $46.77 | 2019 | |
| Pfizer INC. | $36.15 | 2020 | |
| Glaxosmithkline, LLC. | $28.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $19.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.